Viking Therapeutics, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a separate fourth-quarter filing. Viking is a clinical-stage biopharmaceutical company with no approved products or product revenue.
Business context and pipeline
- VK2809: Oral selective thyroid hormone receptor beta agonist. The Phase 2b VOYAGE trial in biopsy-confirmed NASH was underway, targeting about 340 patients; the primary endpoint assesses liver fat change at week 12, with liver histology assessed after 52 weeks.
- VK0214: Candidate for X-linked adrenoleukodystrophy (X-ALD). A Phase 1 single- and multiple-ascending-dose study in healthy subjects began in September 2020. FDA orphan drug designation was previously granted.
- VK5211: Phase 2 hip-fracture study results reported in 2017 showed dose-dependent improvements in lean body mass. Viking intended to pursue partnering or licensing before further clinical studies.
- Other programs include VK0612 for type 2 diabetes and preclinical DGAT-1 and EPOR programs.
Financial performance and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $31.9 million | $23.6 million |
| General and administrative expense | $10.7 million | $9.1 million |
| Total operating expenses | $42.7 million | $32.7 million |
| Net loss | $39.5 million | $25.8 million |
| Basic and diluted net loss per share | $0.54 | $0.36 |
| Net cash used in operating activities | $21.8 million | $24.8 million |
- R&D expense rose 35.5%, primarily reflecting increased clinical-study costs, including $9.5 million of higher clinical-study expense. G&A expense rose 17.6%, principally due to higher stock-based compensation.
- Other income, primarily interest income, was $3.2 million versus $6.9 million in 2019; lower interest income contributed to the larger net loss.
- At December 31, 2020, cash and cash equivalents were $29.1 million and short-term investments were $219.3 million, totaling about $248.4 million. Management said these resources were expected to fund operations through at least the first quarter of 2022.
- Total assets were $256.5 million and total liabilities were $12.2 million. The filing reports no borrowings; liabilities were primarily accounts payable, accrued liabilities and lease obligations. Stockholders’ equity was $244.3 million.
- Cash from investing activities was $41.6 million, mainly net proceeds from investment sales and maturities. Financing activities provided $1.0 million. No shares were sold under the $75 million ATM program through year-end.
- No meaningful operating margin is reported because the company had no revenue and incurred operating losses.
Material changes, outlook and risks
- Compared with 2019, higher clinical development spending and stock-based compensation drove higher operating expenses and a wider net loss. Operating cash use nevertheless declined, partly reflecting working-capital movements and non-cash items.
- Management expected losses to continue and increase as clinical programs advance. Additional capital will be needed to fund operations and ongoing and planned trials; future financing may be unavailable or dilutive. The filing provides no specific financial or trial-result guidance beyond the stated cash runway and study descriptions.
- COVID-19 had affected, and could continue to affect, trial-site initiation, patient enrollment, trial conduct, suppliers and operations. Management said the pandemic’s ultimate financial and operational effects were uncertain.
- Viking depends substantially on licensed technology from Ligand. The agreement includes potential development, regulatory and sales milestone payments of up to approximately $1.54 billion in aggregate, plus tiered single-digit royalties on licensed-product sales; these are contingent obligations, not current debt.
- Principal risks include clinical and regulatory failure or delay, competition, reliance on third-party manufacturers and CROs, intellectual-property protection, financing needs, and the absence of commercial revenue. There were no legal proceedings identified as reasonably expected to have a material adverse effect.
- Management concluded disclosure controls and internal control over financial reporting were effective as of year-end. The auditor did not provide an internal-control attestation because Viking was a non-accelerated filer.
Important facts for investors to verify
- VOYAGE enrollment, execution and results, including the week-12 liver-fat endpoint and 52-week biopsy outcomes.
- VK0214 Phase 1 safety, tolerability and dose-selection results, and the subsequent clinical-development plan.
- Cash burn, investment balances and financing needs relative to the stated runway; confirm the timing and terms of any future capital raises.
- Any material changes to the Ligand license, contingent milestone obligations or royalty terms, and the status of partnering efforts for VK5211.
- Effects of COVID-19 or other operational disruptions on trial timelines, patient enrollment and clinical supply.